blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2301547

EP2301547 - Use of activators of soluble guanylate cyclase for improving wound healing [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  18.05.2012
Database last updated on 05.10.2024
Most recent event   Tooltip18.05.2012Application deemed to be withdrawnpublished on 20.06.2012  [2012/25]
Applicant(s)For all designated states
Bayer Pharma Aktiengesellschaft
Müllerstrasse 178
13353 Berlin / DE
[2011/34]
Former [2011/13]For all designated states
Bayer Schering Pharma AG
Müllerstrasse 178
13353 Berlin / DE
Inventor(s)01 / Krahn, Thomas
Wiener Str.29
58135, Hagen / DE
02 / Stasch, Johannes-Peter
Alfred-Nobel-Str.109
42651, Solingen / DE
03 / Weimann, Gerrit
Am Sonnenhut 79
51109, Köln / DE
04 / Thielemann, Wolfgang
Ziegenburg 1
42107, Wuppertal / DE
05 / Stelte-Ludwig, Beatrix
Görtzheide 10f
42489, Wülfrath / DE
 [2011/13]
Application number, filing date10195559.906.07.2006
[2011/13]
Priority number, dateDE2005103157506.07.2005         Original published format: DE102005031575
[2011/13]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report 
No.:EP2301547
Date:30.03.2011
Language:DE
[2011/13]
Search report(s)(Supplementary) European search report - dispatched on:EP28.02.2011
ClassificationIPC:A61K31/506, A61P17/02
[2011/13]
CPC:
A61K31/506 (EP,US); A61P17/02 (EP); A61P25/02 (EP);
A61P29/00 (EP); A61P3/10 (EP); A61P31/04 (EP);
A61P43/00 (EP); A61P9/00 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2011/13]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Förderung der Wundheilung[2011/13]
English:Use of activators of soluble guanylate cyclase for improving wound healing[2011/13]
French:Utilisation d'activateurs de le guanylate cyclase pour favoriser la guérison des blessures[2011/13]
Examination procedure30.09.2011Examination requested  [2011/45]
01.10.2011Application deemed to be withdrawn, date of legal effect  [2012/25]
08.11.2011Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time  [2012/25]
Parent application(s)   TooltipEP06762453.6  / EP1901732
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060762453) is  11.03.2010
Fees paidRenewal fee
18.04.2011Renewal fee patent year 03
18.04.2011Renewal fee patent year 04
18.04.2011Renewal fee patent year 05
01.08.2011Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]EP1149583  (PFIZER PROD INC [US]) [A] 1-7 * abstract * * paragraphs [0001] , [0008] , [0015] , [0049]; claim 16 * * page 16, lines 13,14 *;
 [A]WO2005011727  (PFIZER LTD [GB], et al) [A] 1-7 * page 8, lines 2,3 * * claims 4,6,10 *;
 [A]WO0030630  (LINDEN BIOTECHNOLOGY INC [US], et al) [A] 1 * abstract * * page 4, lines 7-20 * * page 10, lines 5-18 *;
 [A]WO9608966  (NEW YORK SOCIETY FOR THE RUPTU [US]) [A] 1 * abstract * * page 3, line 12 - page 4, line 3 * * page 24, lines 20-27 *;
 [A]WO2005046725  (BAYER HEALTHCARE AG [DE], et al) [A] 1-7 * the whole document *;
 [A]WO03086407  (BAYER AG [DE], et al) [A] 1-7 * the whole document *
by applicantWO9608966
 WO0006569
 WO0242301
 WO03095451
 WO9637192
 EP0852941
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.